简介：ＴＨＥＲＡＰＥＵＴＩＣＥＦＦＥＣＴＳＯＦｒｈＴＮＦＡＬＯＮＥＡＮＤＩＮＣＯＭＢＩＮＡＴＩＯＮＷＩＴＨ　ＫＥＮＧＳＨＥＮＧＭＹＣＩＮＩＮＥＸＰＥＲＩＭＥＮＴＡＬＨＵＭＡＮＯＶＡＲＩＡＮＣＡＮＣＥＲＺｈａｏＥｎｆｅｎｇ赵恩锋；ＺｈｏｕＭｅｉｑｉｎｇ周美清...

简介：GFAPisaspecificantigenofglialelement,butAlpha-1-antichymotrypsinhasnotbeenreportedintheliterature.Alpha-1-antichymotrypsinwasguidedbyGFAPusingPAPmethodtotheastrocytesof137gliomas.120(87%)gliomaswerepositiveforAlpha-1-antichymotrypsin.Ofthese120gliomas,86(72%)gavediffusedistribution,17(14%)gavefocaldistribution,and17(14%)gavescattereddistributions.Alpha-1-antichymotrypsiningliomatissuemaybeanimportanttumormarkerfordiagnosis.

简介：

简介：Objective:TodeterminewhetherInterferon-alpha-2b(IFN-α2b)canmodulatetheautophagicresponseinhepatocellularcarcinomacells.Methods:HepatocellularcarcinomacellsweretreatedwithIFN-α2b.Autophagywasassessedbyacridineorangestaining,GFP-LC3dottedassay,transmissionelectronmicroscopyandimmunoblotting.Results:AcridineorangestainingshowedthatIFN-α2btriggeredtheaccumulationofacidicvesicularandautolysosomesinHepG2cells.TheacridineorangeHepG2cellratioswere(4.3±1.0)%,(6.9±1.4)%,and(13.1±2.3)%,respectively,aftertreatmentwith100,1,000,and10,000IU/mLIFN-α2bfor48h.AmarkedlypunctatepatternwasobservedinHepG2cellstreatedwith10,000IU/mLIFN-α2bfor48h,butonlydiffuseandweaklyfluorescentGFP-LC3punctawasobservedincontrolcells.HepG2cellstreatedwith10,000IU/mLIFN-α2bfor48hdevelopedautophagosome-likecharacteristics,includingsingle-ordouble-membranevacuolescontainingintactanddegradedcellulardebris.TheBeclin1andLC3-IIproteinexpressionwasup-regulatedbyIFN-α2btreatment.Conclusion:Autophagycanbeinducedinadose-dependentmannerbytreatmentwithIFN-α2binHepG2cells,andtheBeclin1signalingpathwaywasstimulatedbyIFN-α2b.

简介：Objective:Toinvestigatetheimpactofbeta-elemeneinjectiononthegrowthandalpha-tubuleofhumanhepatocarcinomaHepG2cells.Methods:CellproliferationwasassessedbyMTTassay.Cellcycledistributionwasdetectedbyflowcytometry(FCM).ThemRNAexpressionofalpha-tubulinwasmeasuredbyRT-PCR.Westernblotanalysiswasusedtodetermineproteinexpressionofalpha-tubulinandthepolymerizationoftubulin.Results:Beta-elemeneinjectioninhibitedHepG2cellsproliferationinadose-andtime-dependentmanner;FCManalysisindicatedbeta-elemeneinjectioninducedcellcyclearrestedatSphase.RT-PCRandwesternblotanalysisshowedthatbeta-elemeneinjectiondown-regulatedalpha-tublinatbothmRNAandproteinlevels,presentingadose-dependentmanner.Moreover,beta-elemeneinjectionreducedthepolymerizationofmicrotubulesinadose-dependentmanner.Conclusions:Beta-elemeneinjectioncaninhibittheproliferationofhepatomaHepG2cellsandinducecellapoptosis,themechanismmightbepartlyrelatedtothedown-regulationofalpha-tubulinandinhibitionofmicrotubularpolymerization.

简介：目的观察重组改构人肿瘤坏死因子-NC（rhTNF-NC）注射液单药治疗恶性肿瘤的临床疗效、不良反应以及对患者生活质量的影响。方法入组的320例患者中,可进行疗效评价310例,脱落9例,剔除1例。310例患者中,恶性淋巴瘤71例,恶性胸腹水169例,恶性黑色素瘤18例,肺癌20例,肝癌12例,乳腺癌10例,结肠癌7例和肾癌3例。恶性淋巴瘤、恶性黑色素瘤、肺癌等实体肿瘤患者给予静脉注射rhTNF-NC60万~90万IU/m2,最大剂量≤100万IU/m2,1次/d,连用4周;恶性胸腹水患者予以胸腹腔注射rhTNF-NC,剂量为200万~300万IU/次,1~2次/周,连用2~3周;体表肿瘤（主要为恶性黑色素瘤）患者在rhTNF-NC静脉给药的同时予以瘤体内或瘤床注射,推荐注射剂量为50万~100万IU/次,2~3次/周。结果可评价的患者310例,其中恶性胸腹水169例,实体肿瘤141例。实体瘤患者中获CR2例,PR21例,有效率（RR）为16.3%（23/141）,疾病控制率（DCR）为79.4%（112/141）。恶性淋巴瘤的RR为28.2%（20/71）,DCR为84.5%（60/71）;恶性黑色素瘤的RR为11.1%（2/18）,DCR为83.3%（15/18）;肺癌无CR病例,获PR1例,MR2例;肾癌获MR1例;肝癌、结肠癌、乳腺癌均未见明显疗效。恶性胸腹水病例中获CR15例,PR102例,RR为69.2%（117/169）,DCR为98.8%（167/169）;其中,恶性胸水的RR为74.5%（105/141）,恶性腹水为42.9%（12/28）。全组患者治疗后的KPS评分较治疗前有显著提高（P=0.013）,特别是恶性胸水患者提高更为明显。主要不良反应为发热（38.8%）和寒战（23.5%）,绝大多数为1、2级。结论注射用rhTNF-NC治疗恶性淋巴瘤和恶性胸腹水疗效明确,对肺癌、恶性黑色素瘤也有一定疗效,并能够明显改善各种癌症患者的生活质量,安全性良好。